Clinical Trial Update: A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating vemurafenib with cobimetinib (GDC-0973) in BRAFV600E mutation-positive metastatic melanoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• GDC-0973 (Cobimetinib) (cobimetinib)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2016-06-17